Text size
this story is by
Vadim Sviderski
Vaxil BioTherapeutics, an early-stage start-up aspiring to develop a therapeutic vaccine for cancer, has begun trading on the Tel Aviv Stock Exchange through a reverse merger with Sheldonco, a listed shell company.
